1. 調査手法および範囲
1.1. 調査手法
1.2. 調査目的およびレポートの範囲
2. 定義および概要
3. エグゼクティブサマリー
3.1. 製品種類別抜粋
3.2. 疾患別抜粋
3.3. エンドユーザー別抜粋
3.4. 地域別抜粋
4. ダイナミクス
4.1. 影響因子
4.1.1. 推進要因
4.1.1.1. 心血管疾患の有病率の増加
4.1.1.2. XX
4.2. 阻害要因
4.2.1. 高度な代替品の利用可能性
4.3. 機会
4.3.1. 影響分析
5. 業界分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
6. 製品種類別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率（％）製品種類別
6.1.2. 市場魅力度指数、製品種類別
6.2. 植込み型単室ペーサー*
6.2.1. はじめに
6.2.2. 市場規模分析および前年比成長率分析（％）
6.3. 外部単室ペーサー
7. 疾患別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（％）、疾患別
7.1.2. 市場魅力度指数、疾患別
7.2. 徐脈*
7.2.1. はじめに
7.2.2. 市場規模分析および前年比成長率（％）
7.3. 心房細動
7.4. 心ブロック
7.5. 洞不全症候群
7.6. その他
8. エンドユーザー別
8.1. はじめに
8.1.1. エンドユーザー別市場規模分析および前年比成長率（％）
8.1.2. エンドユーザー別市場魅力度指数
8.2. 病院*
8.2.1. はじめに
8.2.2. 市場規模分析および前年比成長率（％）
8.3. 外来外科センター（ASC）
8.4. 心臓クリニック
9. 地域別
9.1. はじめに
9.1.1. 市場規模分析および前年比成長率分析（％）、地域別
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. はじめに
9.2.2. 主要地域別の動向
9.2.3. 市場規模分析および前年比成長率分析（％）、製品種類別
9.2.4. 市場規模分析および前年比成長率分析（％）、疾患別
9.2.5. 市場規模分析および前年比成長率分析（％）、エンドユーザー別
9.2.6. 市場規模分析および前年比成長率分析（％）、国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主要地域特有の力学
9.3.3. 市場規模分析および前年比成長率分析（％）、製品種類別
9.3.4. 市場規模分析および前年比成長率分析（％）、疾患別
9.3.5. 市場規模分析および前年比成長率分析（％）、エンドユーザー別
9.3.6. 市場規模分析および前年比成長率分析（％）、国別
9.3.6.1. ドイツ
9.3.6.2. 英国
9.3.6.3. フランス
9.3.6.4. スペイン
9.3.6.5. イタリア
9.3.6.6. ヨーロッパのその他地域
9.3.7. 南アメリカ
9.3.7.1. はじめに
9.3.7.2. 主要地域別の動向
9.3.7.3. 市場規模分析および前年比成長率分析（％）、製品種類別
9.3.7.4. 市場規模分析および前年比成長率分析（％）、疾患別
9.3.7.5. 市場規模分析および前年比成長率分析（％）、エンドユーザー別
9.3.7.6. 国別の市場規模分析および前年比成長率（％）
9.3.7.6.1. ブラジル
9.3.7.6.2. アルゼンチン
9.3.7.6.3. 南米のその他地域
9.3.8. アジア太平洋
9.3.8.1. はじめに
9.3.8.2 主要地域別の動向
9.3.8.3 市場規模分析および前年比成長率分析（％）、製品種類別
9.3.8.4 市場規模分析および前年比成長率分析（％）、疾患別
9.3.8.5 市場規模分析および前年比成長率分析（％）、エンドユーザー別
9.3.8.6 市場規模分析および前年比成長率分析（％）、国別
9.3.8.6.1 中国
9.3.8.6.2 インド
9.3.8.6.3 日本
9.3.8.6.4 韓国
9.3.8.6.5 アジア太平洋地域その他
9.3.9 中東およびアフリカ
9.3.9.1 はじめに
9.3.9.2 主要地域特有のダイナミクス
9.3.9.3 市場規模分析および前年比成長率分析（％）、製品種類別
9.3.9.4 市場規模分析および前年比成長率分析（％）、疾患別
9.3.9.5 市場規模分析および前年比成長率分析（％）、エンドユーザー別
10. 競合状況
10.1. 競合シナリオ
10.2. 市場ポジショニング/シェア分析
10.3. 合併・買収分析
11. 企業プロフィール
Medtronic
Boston Scientific Corporation
Abbott Laboratories
Biotronik SE & Co. KG
MicroPort Scientific Corporation
LivaNova PLC
Osypka Medical GmbH
Lepu Medical Technology
Oscor Inc
Shree Pacetronix Ltd
リストは網羅的なものではありません
12. 付録
12.1. 当社およびサービスについて
12.2. お問い合わせ
The global single-chamber pacemaker market reached US$ 2.20 Billion in 2023 and is expected to reach US$ 2.77 Billion by 2031, growing at a CAGR of 3.0% during the forecast period 2024-2031.
Single-chamber pacemaker is a device that provides electrical impulses to one heart chamber, namely the atrium or the ventricle. This type of pacemaker is most helpful to most patients suffering from slow heart rate (bradycardia) or any other rhythm disorder that limits its ability to maintain an adequate rate in the heart. It comprises a pulse generator-a battery with circuitry-and a lead for electrical signals passing to the chamber of interest. Clinicians consider single-chamber systems simpler devices than dual-chamber or biventricular systems for patients whose rhythm irregularities do not require synchronization between multiple chambers. Minimal-invasive technology provides reliable, cost-effective heart rhythm management.
Market Dynamics: Drivers & Restraints
Rise in the Prevalence of Cardiovascular Diseases
Rising numbers of arrhythmias, particularly such conditions as bradyarrhythmias or heart block, significantly contribute to the global expansion of the single-chamber pacemaker market. Rising elderly population further increases the incidence of cardiovascular conditions as older adults suffer more from the rhythm-related disorder of the heart.
Effective management of the rhythm-related heart disorders was made possible with single-chamber pacemakers, which became essential in providing heart function to patients in need. They also have been fueled by a greater demand for awareness of a patient's early diagnosis and treatment in cardiac problems. Most times, single-chamber pacemakers are single enough to provide effective and reliable, but cost-effective therapy in resource-strapped regions, guaranteeing their share in the market.
For instance, according to British Heart Foundation, cardiovascular disease remains the leading cause of death in both men and women throughout the world. In the year of 2023 the world’s population is 8 billion out of those approximately 620 Billion are suffering from cardiac and vascular illnesses everywhere across the globe. Every year approximately sixty Billion individuals in the globe will be diagnosed with heart or circulatory disease. It has been suggested that one out of every 13 patients has heart or circulatory ailments. Cardiovascular diseases are responsible for roughly 1 out of 3 deaths in the world; these accounted for - over 20.5 Billion deaths worldwide in 2021 – which is 56,000 lost lives every day or almost one every 1 and ½ second.
Availability of Advanced Alternatives
pacemakers, for more extensive heart rhythm management. These devices synchronize electrical impulses into several chambers of the heart, which has be proved to be more beneficial for patients with complex arrhythmias or heart failure. Hence, healthcare providers would probably favor advanced options over single-chamber pacemakers, especially in developed economic markets that have higher healthcare budgets.
Moreover, other impediments in the adoption of these devices would be high prices associated with the implantation and ongoing maintenance of the pacemaker where there is a lack of sufficient skilled professionals in some resource-limited areas that lead to constraints in costing. There are also fears of complications such as those of infection, lead dislocation, and malfunction of the devices, particularly among patients and their physicians from resource-constrained settings.
Segment Analysis
The global single-chamber pacemaker market is segmented based on product type, indication, end user, and region.
Product type:
Implantable single-chamber pacemakers segment is expected to dominate the single-chamber pacemaker market share
The implantable single-chamber pacemakers segment holds a major portion of the single-chamber pacemaker market share and is expected to continue to hold a significant portion of the single-chamber pacemaker market share during the forecast period.
An implantable single-chamber pacemaker is a primary source in the single-chamber pacemakers for managing long-term cardiac rhythms with an ideal solution for disorders such as bradycardia and heart block. It is surgically implanted under the skin with a lead connected to either the atrium or ventricle for heart rate regulation. Due to their ability to read and respond to the electrical activity of the heart, they are critical for the patient who requires constant rhythm management. It is mainly a long-term solution for heart rhythm disorders.
The main reason these devices have energy demand is their durability, better extensions, and utility in terms of features such as MRI compatibility and remote monitoring. These devices gained an entry into developed and emerging markets, thus being established as essential in this segment in the single-chamber pacemaker market.
End User:
Hospitals segment is the fastest-growing segment in the single-chamber pacemaker market share
The hospitals segment is the fastest-growing segment in the single-chamber pacemaker market share and is expected to hold the market share over the forecast period.
Hospitals will constitute some of the main areas in terms of the Global Single-Chamber Pacemaker Market: diagnosis, implantation, and follow-up care for pacemaker patients. They provide necessary infrastructure such as specialized cardiac care units and skilled medical personnel, including cardiologists and electrophysiologists, trained to manage pacemaker procedures. Hospitals are often the first point of contact for patients with arrhythmias or other cardiac complaints, triggering early diagnosis and timely intervention.
Furthermore, hospitals propel the advanced technologies and treatment protocols adoption, ensuring that the patients receive the latest pacemaker models enhanced with better functionality. Additionally, hospitals sustain growth in the market by taking part in clinical trials that help advance pacemaker technology and offering training programs that uphold the growth of expertise in the implanting and management of pacemaker devices.
Geographical Analysis
North America is expected to hold a significant position in the Single-Chamber Pacemaker market share
North America holds a substantial position in the Single-Chamber Pacemaker market and is expected to hold most of the market share due to increasing incidences of cardiovascular disorders and new arrhythmias due to research developments, in the wake of a growing elderly population. Highly advanced health care infrastructure, along with greater access to high-end technologies, contribute significantly to the growth of the market. Also, strong healthcare reimbursement policies in countries such as the United States and Canada further make pacemaker therapies more accessible. Continued collaboration on research and development by prominent market players with favourable regulatory approvals can also further boost market growth in this region.
For instance, in July 2023, Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to expand the indication for current-generation INGEVITY Pacing Leads. These are thin wires placed inside the heart and connected to an implantable device and allow conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) in connection with a single- or dual-chamber pacemaker.
Europe is growing at the fastest pace in the Single-Chamber Pacemaker market
Europe holds the fastest pace in the Single-Chamber Pacemaker market and is expected to hold most of the market share.
Europe, a convergence of an aging populace and a rise in lifestyle-related heart problems will drive the Single-Chamber Pacemaker Market's growth. The strong public healthcare systems make countries such as Germany, France, and the UK perfect beneficiaries of the growing market of cardiac care. Ongoing improvements in pacemaker technology, to make more compact devices with greater battery life, also play an influential role. Furthermore, the European Union's efforts in fostering new innovations in medical devices and the presence of well-known international medical-device manufacturers contribute to the growth of the market.
For instance, in July 2023, BIOTRONIK announced FDA approval for its suite of Amvia Edge pacemakers and CRT-Ps, the company's new technology for cardiac rhythm management. Introducing innovative patient-centric clinical solutions, it is also the most efficient automated workflow. Amvia Edge is the market's smallest single-chamber MR conditional pacemaker.
Competitive Landscape
The major global players in the single-chamber pacemaker market include Medtronic, Boston Scientific Corporation, Abbott Laboratories, Biotronik SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, Osypka Medical GmbH, Lepu Medical Technology, Oscor Inc, Shree Pacetronix Ltd among others.
Emerging Players
The emerging players in the single-chamber pacemaker market include Medico, EPMed, CureMetrix, Zoll Medical and among others.
Key Developments
• In November 2024, Abbott recently announced the launch of the AVEIR VR single-chamber ventricular leadless pacemaker, meant for treating patients with slow heart rhythms in India. This pacemaker has already received approval from the Central Drugs Standard Control Organization (CDSCO) in India. It is also US Food and Drug Administration (FDA) approved.
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global single-chamber pacemaker market report would provide approximately 70 tables, 65 figures, and 184 pages.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product type
3.2. Snippet by Indication
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Prevalence of Cardiovascular Diseases
4.1.1.2. XX
4.2. Restraints
4.2.1. Availability of Advanced Alternatives
4.3. Opportunity
4.3.1. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Product type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
6.1.2. Market Attractiveness Index, By Product type
6.2. Implantable Single-Chamber Pacemakers*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. External Single-Chamber Pacemakers
7. By Indication
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.1.2. Market Attractiveness Index, By Indication
7.2. Bradycardia*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Atrial Fibrillation
7.4. Heart Block
7.5. Sick Sinus Syndrome
7.6. Others
8. By End User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers (ASCs)
8.4. Cardiac Clinics
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.3.7. South America
9.3.7.1. Introduction
9.3.7.2. Key Region-Specific Dynamics
9.3.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
9.3.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.6.1. Brazil
9.3.7.6.2. Argentina
9.3.7.6.3. Rest of South America
9.3.8 Asia-Pacific
9.3.8.1 Introduction
9.3.8.2 Key Region-Specific Dynamics
9.3.8.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
9.3.8.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.8.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.8.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.8.6.1 China
9.3.8.6.2 India
9.3.8.6.3 Japan
9.3.8.6.4 South Korea
9.3.8.6.5 Rest of Asia-Pacific
9.3.9 Middle East and Africa
9.3.9.1 Introduction
9.3.9.2 Key Region-Specific Dynamics
9.3.9.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
9.3.9.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.9.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Medtronic*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Boston Scientific Corporation
11.3. Abbott Laboratories
11.4. Biotronik SE & Co. KG
11.5. MicroPort Scientific Corporation
11.6. LivaNova PLC
11.7. Osypka Medical GmbH
11.8. Lepu Medical Technology
11.9. Oscor Inc
11.10. Shree Pacetronix Ltd
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us
*** シングルチャンバペースメーカーの世界市場に関するよくある質問(FAQ) ***
・シングルチャンバペースメーカーの世界市場規模は？
→DataM Intelligence社は2023年のシングルチャンバペースメーカーの世界市場規模を22億米ドルと推定しています。
・シングルチャンバペースメーカーの世界市場予測は？
→DataM Intelligence社は2031年のシングルチャンバペースメーカーの世界市場規模を27億7000万米ドルと予測しています。
・シングルチャンバペースメーカー市場の成長率は？
→DataM Intelligence社はシングルチャンバペースメーカーの世界市場が2024年～2031年に年平均3.0%成長すると展望しています。
・世界のシングルチャンバペースメーカー市場における主要プレイヤーは？
→「Medtronic、Boston Scientific Corporation、Abbott Laboratories、Biotronik SE & Co. KG、MicroPort Scientific Corporation、LivaNova PLC、Osypka Medical GmbH、Lepu Medical Technology、Oscor Inc、Shree Pacetronix Ltdなど ...」をシングルチャンバペースメーカー市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
